Preferred Label : GAA protein, human;

MeSH note : Defects in the gene for this protein cause glycogen storage disease II, also known as Pompe disease, RefSeq NM_000152;

CISMeF synonym : genzyme brand of recombinant human alglucosidase alfa;

MeSH synonym : LYAG protein, human; acid maltase, human; glucosidase, alpha; acid (Pompe disease, glycogen storage disease type II), human; lysosomal alpha-glucosidase, human; acid alpha-glucosidase, human;

MeSH hyponym : rhGAA; recombinant human acid alpha-glucosidase;

MeSH Related Number : myozyme; alglucosidase alfa; EC 3.2.1.20; DTI67O9503;

Registry Number MeSH : EC 3.2.1.20;

Related CAS MeSH : EC 3.2.1.20 (alglucosidase alfa); EC 3.2.1.20 (Myozyme);

related registry number list (CISMeF) : EC 3.2.1.20;

Is substance : O;

UNII : EC 3.2.1.20;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3498146/fr/myozyme-alglucosidase-alfa-maladie-de-pompe-deficit-en-glucosidase-acide
2024
false
false
false
France
GAA protein, human
adult
adolescent
child
treatment outcome
insurance, health, reimbursement
enzyme replacement therapy
infusions, intravenous
alglucosidase alfa
glycogen storage disease type II, infantile
adult glycogen storage disease type II
Glycogen storage disease type II late onset (disorder)
evaluation of the transparency committee
glycogen storage disease type ii
alglucosidase alfa

---
https://ansm.sante.fr/tableau-marr/avalglucosidase-alfa
2023
false
false
false
France
French
guidelines for drug use
risk management
Infusion-Related Reaction
medication errors
Avalglucosidase Alfa
infusions, intravenous
home infusion therapy
continuity of patient care
enzyme replacement therapy
GAA protein, human
avalglucosidase alfa
monitoring, immunologic
glycogen storage disease type ii

---
https://ansm.sante.fr/tableau-atu-rtu/nexviadyme-100-mg-poudre-pour-solution-a-diluer-pour-perfusion
2021
false
false
false
France
French
summary of product characteristics
package leaflet
Avalglucosidase Alfa
Avalglucosidase Alfa
adult
child
glycogen storage disease type ii
infusions, intravenous
alpha-Glucosidases
alpha-Glucosidases
dna, recombinant
GAA protein, human
GAA protein, human

---
https://www.has-sante.fr/portail/jcms/c_2754216/fr/myozyme-alpha-alglucosidase-enzymotherapie-substitutive
https://www.has-sante.fr/portail/jcms/c_2754216/fr/myozyme
2017
false
false
France
English
French
guidelines for drug use
child
glycogen storage disease type ii
treatment outcome
alpha-Glucosidases
GAA protein, human
enzyme replacement therapy
alpha-Glucosidases
alglucosidase alfa
recombinant proteins
GAA protein, human
evaluation of the transparency committee
infusions, intravenous
orphan drug production
adult
survival analysis
risk management

---
http://www.has-sante.fr/portail/jcms/c_2659919/fr/maladie-de-pompe
http://www.has-sante.fr/portail/jcms/c_2659918/fr/pnds-maladie-de-pompe
2016
false
false
false
France
French
practice guideline
glycogen storage disease type ii
general practice
glycogen storage disease type ii
glycogen storage disease type ii
infant
child
adolescent
signs and symptoms
glycogen storage disease type ii
adult
diagnosis, differential
truth disclosure
glycogen storage disease type ii
GAA protein, human
alpha-Glucosidases
GAA protein, human
alpha-Glucosidases
physical therapy modalities
pregnancy
watchful waiting
continuity of patient care
general practitioners

---
http://www.has-sante.fr/portail/jcms/c_1359745/myozyme
http://www.has-sante.fr/portail/upload/docs/application/pdf/2013-02/myozyme_reeval_avis2correct_materiel_ct12440.pdf
http://www.has-sante.fr/portail/jcms/c_446700/myozyme
http://www.has-sante.fr/portail/jcms/c_967981/myozyme
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-09/myozyme_ct_7575.pdf
2013
France
English
French
glycogen storage disease type ii
treatment outcome
alpha-Glucosidases
GAA protein, human
enzyme replacement therapy
alpha-Glucosidases
alglucosidase alfa
recombinant proteins
GAA protein, human
alpha-Glucosidases
evaluation of the transparency committee
infusions, intravenous
orphan drug production
adult
survival analysis
follow-up studies
risk management

---
https://www.ema.europa.eu/medicines/human/EPAR/Myozyme
2012
United Kingdom
English
French
syndication feed
glycogen storage disease type ii
alpha-Glucosidases
alpha-Glucosidases
alpha-Glucosidases
treatment outcome
drug evaluation
orphan drug production
infusions, intravenous
child
adolescent
adult
aged
alpha-Glucosidases
alpha-Glucosidases
pregnancy
breast feeding
drug compounding
drug labeling
drug approval
GAA protein, human
alglucosidase alfa
alpha-Glucosidases
drug evaluation
package leaflet
summary of product characteristics

---
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2007/14464a-fra.php
Canada
French
alpha-Glucosidases
GAA protein, human
alpha-Glucosidases
pharmacovigilance note

---
http://www.cetl.net/a-la-une/article/recommandations-du-cetpompe
http://www.cetl.net/IMG/pdf/RECO_CETP_-_Modalites_d_utilisation_du_Myosyme001.pdf
2011
France
French
alpha-Glucosidases
GAA protein, human
glycogen storage disease type ii
continuity of patient care
practice guideline

---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00098
2011
false
false
false
Canada
GAA protein, human
drug information
powders
alpha-Glucosidases

---
http://www.has-sante.fr/portail/jcms/c_979774/myozyme-alpha-alglucosidase-enzyme-recombinante
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-07/myozyme_-_ct-7575.pdf
2010
France
French
GAA protein, human
alpha-Glucosidases
alglucosidase alfa
glycogen storage disease type ii
infusions, intravenous
treatment outcome
GAA protein, human
alpha-Glucosidases
orphan drug production
rare diseases
enzyme replacement therapy
alpha-Glucosidases
evaluation of the transparency committee
guidelines for drug use

---
https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_Myozyme_June-14-2007_f.pdf
2007
Canada
French
glycogen storage disease type ii
alpha-Glucosidases
GAA protein, human
alglucosidase alfa
alpha-Glucosidases
drug evaluation

---
Nous contacter.
01/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.